Prof. Dr. Essam Fadel Alwan, a faculty member at the Institute of Genetic Engineering and Biotechnology for Postgraduate Studies at the University of Baghdad, has recently obtained a patent for his study entitled “New therapeutic substance for different cancer cells using natural Glycoquine diagnosed and purified from the leaves of Bauhinia variegata”. The patent aimed at the experimental application of the treatment of cancerous tumors using Glycoquine purified from this plant.
The results showed that when examining the effectiveness of Glycoquine to stimulate apoptosis in cancer cells HepG2, it increases both the permeability of mitochondrial membranes and the stimulation of the release of cytochrome C protein, which is one of the essential proteins in the process of the programmed cell death. The therapeutic results showed very high efficacy in the treatment of the tumors of milk glands in mice AN3 through the use of Glycoquine diagnosed and purified from the leaves of Bauhinia variegata by increasing the survival period, lifetime, reducing tumor sizes and inhibiting tumor growth compared to the control group that did not receive such a treatment. Also the results of the histological examination of the groups treated with Glycoquine showed positive results by stimulating a programmed cell death, reducing the process of necrosis (the death of body tissue), as well as reducing the abnormal forms of cancer cells in the tumor mass sections of mice, and also gave positive results in the liver of mice affected by reducing inflammation resulting from cancer.